Navigation Links
Triax Pharmaceuticals Launches New Mid-Potency Corticosteroid Vehicle, Locoid Lotion 0.1%
Date:8/12/2008

Locoid Lotion was recently introduced at the Summer American Academy of Dermatology Meeting, in Chicago, Illinois, for the treatment of mild-to-moderate atopic dermatitis in pediatric to adult patients. Triax Pharmaceuticals, LLC, the marketers of Locoid Lipocream (hydrocortisone butyrate 0.1%) a leading mid-potency brand in corticosteroids, recently launched the new product to cover larger and hairy affected areas with an elegant, non-greasy application to treat atopic dermatitis.

Crawford, NJ (PRWEB) August 12, 2008 -- A new product to treat http://www.locoid.com/ [atopic dermatitis] in adult to http://www.locoid.com/ [pediatric] patients as young as three months of age was recently introduced. Locoid Lotion, launched by http://www.triaxpharma.com/ [Triax Pharmaceuticals, LLC] - the marketers of the leading mid-potency corticosteroid brand Locoid Lipocream (hydrocortisone butyrate 0.1%) - is a new lotion vehicle especially designed to cover larger and hairy affected areas with an elegant, non-greasy application to treat milt to moderate atopic dermatitis. 1.

http://www.locoid.com/ [Atopic dermatitis] (AD) is very common in the United States. It affects nearly 15 million people (1% to 3% of adults and 10% to 20% of children).1, and accounts for 10 to 20 percent of all visits to dermatologists. The key symptom is pruritus (itching), leading to the description of AD as "the itch that rashes." Itching is fairly constant during daytime hours and worsens at night, causing sleep disturbances and discomfort. For parents of children with AD, it is the number one reason for days of missed work in the United States and it is a common cause of workplace disability for all adults. People who live in cities and in drier climates appear more likely to develop http://www.locoid.com/ [atopic dermatitis].2.

http://www.locoid.com/ [Locoid Lotion] and Locoid Lipocream have been formulated with high concentration of barrier-enhancing lipids. This unique feature provides skin barrier restorative properties for a wide range of patients.

Locoid® Lotion is the ONLY class 5 corticosteroid indicated for pediatric patients 3 months of age and older. It has been proven to provide significant relief of all AD symptoms in pediatric and adult patients. In 89% of patients, symptoms of skin-barrier disruption were eliminated or reduced to mild. By Day 8, average pruritis-symptom scores were reduced to less than mild2.

Topical Corticosteroids are widely used in the treatment of mild to moderate inflammatory skin diseases. Locoid® Lotion has a wide range of benefits which include the following:

  • Easy to apply and rapidly absorbed, which in turn, makes it easy to spread over affected areas, including large and hairy areas. The cosmetic acceptability promotes patient compliance3.
  • Promotes hydration and enhances penetration of the active drug.
  • Non-halogenated, which allows for low risk of potential side effects.
  • Unlike the majority of topical corticosteroids, Locoid® Lotion contains no irritants such as propylene glycol, lanolin, or imidurea and is formulated in a non-irritating and fragrance-free base.

Dr. Adelaide Hebert, a dermatologist based in Houston, Texas remarks, "Locoid Lotion has unique properties, and is an ideal product for certain hard to treat areas such as the chest, the arms, and the legs."

Locoid® Lotion is available by prescription through pharmacies nationwide in a 2 fl. oz. bottle (4 fl. oz. to follow soon).

Reversible HPA axis suppression may occur with the potential for corticosteroid insufficiency. Consider periodic evaluations for HPA axis suppression if applied to large surface areas or used under occlusion. Systemic effects of topical corticosteroids may also include manifestations of Cushing's syndrome, hyperglycemia, and glucosuria. Pediatric patients may be more susceptible to systemic toxicity due to their large skin surface-to-body-mass ratios. Initiate appropriate therapy if a concomitant skin infection develops. Discontinue use if irritation develops.

About Triax Pharmaceuticals, LLC
Triax Pharmaceuticals is a specialty pharmaceutical company with integrated sales, marketing, and development expertise that markets a portfolio of branded dermatological products. Triax focuses on marketing dermatology products in the United States. Triax sales force is comprised of dermatology sales professionals nationwide. Triax Pharmaceuticals, LLC recently launched its fourth product, Locoid® Lotion .

In addition to industry leader Locoid Lipocream and new Locoid® Lotion, Triax Pharmaceuticals also markets two products in the acne category:

http://www.tretinx.com/ [Tretin-X® (tretinoin)] Kit is available in 0.025% cream, 0.05% cream, 0.1% cream, 0.01% gel, and 0.025% gel. Each kit contains Tretinoin cream or gel along with two cosmetic products included at no additional cost to the patient: T3™ Foaming Cleanser and T3 Soothing Moisturizer.

http://www.minocinpac.com [Minocin® (minocycline HCl) Pellet-filled Capsules Professional Acne Care (P.A.C.)]. The MINOCIN PAC system contains a 60 count bottle of Minocin Pellet-Filled Capsules (50 mg or 100 mg) and three skincare products (at no additional cost to the patient).

1Matheson R, Kempers S, Breneman D, et al. Hydrocortisone butyrate 0.1% lotion in the treatment of atopic dermatitis in pediatric subjects. J Drugs Dermatol. 2008; 7:266-271.
2 http://www.niams.nih.gov/Health_Info/Atopic_Dermatitis/default.asp#link_b
3 Fowler JF Jr. Hydrocortisone butyrate 0.1% cream in the treatment of chronic dermatitis. Cutis 2005; 75:125-131.

For more information on Locoid® Lotion for adult to pediatric patients with atopic dermatitis, please contact Peter Volk or Aleen Hosdaghian of Triax Pharmaceuticals, LLC, 908.372.0500.
See www.locoid.com for full prescribing information.

# # #

Read the full story at http://www.prweb.com/releases/2008/08/prweb1190714.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Triax Pharmaceuticals Launches New Mid-Potency Corticosteroid Vehicle, Locoid  Lotion 0.1% 
(Date:3/22/2017)... ... March 22, 2017 , ... HealthiPASS, Inc., announces ... creating a positive patient experience. , HealthiPASS has further enhanced its predictive ... by helping them understand their financial responsibility. “Our latest release focuses on ...
(Date:3/22/2017)... CA (PRWEB) , ... March 22, 2017 , ... Nearly ... should not undergo PSA (prostate-specific antigen) screening, the cancer screening continues to stir controversy. ... 2008 because it found that the risks outweighed the benefits. Now, news from ...
(Date:3/22/2017)... ... , ... The National Association for Business Resources (NABR) has recently ... in Wellness® companies for 2017. , American Specialty Health (ASH) was honored ... for its employees. ASH is one of only nine other San Diego companies being ...
(Date:3/22/2017)... ... March 22, 2017 , ... Winter ... reduces pigmentation to enhance surgical and nonsurgical procedures—Lytera 2.0 by SkinMedica. Lytera 2.0 ... the face, neck and décolletage in as little as 4 weeks. Skin pigmentation ...
(Date:3/20/2017)... ... ... The topic of healthcare in America has become one of the most ... is that they are still left without the health insurance coverage they need in ... that an unfortunate side-effect of this scenario is that hospital emergency rooms and urgent ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... , March 22, 2017 ... the growing legal cannabis industry is strongly contributing to ... provides comprehensive analysis and reporting for the cannabis industry, ... create more than a quarter million jobs for American ... $7.2 billion in 2016, and is projected to grow ...
(Date:3/22/2017)... March 22, 2017  As the world,s leading non-profit ... Society (LLS) has played a role in most therapies ... which are even helping patients with other cancers and ... significant investment in cutting-edge research – more than $1 ... grow with the record-breaking sum of $4.1 million raised ...
(Date:3/22/2017)... SANTA CLARA, Calif. , March 22, 2017 ... diagnostic cardiology  solutions segment, Frost & Sullivan recognizes ... Sullivan Company of the Year Award. GE Healthcare,s ... offer end-to-end cardiac solutions has allowed it to ... competitive cardiac monitoring products space. In addition to ...
Breaking Medicine Technology: